Clinical Trial Update: Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating lisdexamfetamine dimesylate for adults with ADHD and co-occurring anxiety and depressive disorders has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Attention Deficit Hyperactivity Disorder
• Depressive Disorders

Drugs mentioned

• Lisdexamfetamine dimesylate (Vyvanse) (lisdexamfetamine dimesylate)

Snippet

Sponsor: Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada | Conditions: Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | Phase 4 | Status: COMPLETED